Heart Failure Treatment in 2023: Is There a Place for Lipid
Lowering Therapy?

J 2023

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

POLOCZKOVÁ, Hana a Jan KREJČÍ

Základní údaje

Originální název

Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?

Autoři

POLOCZKOVÁ, Hana (203 Česká republika, domácí) a Jan KREJČÍ (203 Česká republika, domácí)

Vydání

CURRENT ATHEROSCLEROSIS REPORTS, PHILADELPHIA, CURRENT MEDICINE GROUP, 2023, 1523-3804

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 5.800 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133673

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s11883-023-01166-3

UT WoS

001118155800003

Klíčová slova anglicky

Heart failure; Dyslipidemia; Lipid lowering therapy; Statins; PCSK9 inhibitors

Štítky

14110115, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 2. 2024 14:12, Mgr. Tereza Miškechová

Anotace

V originále

Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.

Návaznosti

LX22NPO5104, projekt VaV

Název: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění (Akronym: CarDia)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Národní institut pro léčbu metabolických a kardiovaskulárních onemocnění, 5.1 EXCELES

Citovat

POLOCZKOVÁ, Hana a Jan KREJČÍ. Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? CURRENT ATHEROSCLEROSIS REPORTS. PHILADELPHIA: CURRENT MEDICINE GROUP, 2023, roč. 25, č. 12, s. 957-964. ISSN 1523-3804. Dostupné z: https://dx.doi.org/10.1007/s11883-023-01166-3.

@article{2379567,
   author = {Poloczková, Hana and Krejčí, Jan},
   article_location = {PHILADELPHIA},
   article_number = {12},
   doi = {http://dx.doi.org/10.1007/s11883-023-01166-3},
   keywords = {Heart failure; Dyslipidemia; Lipid lowering therapy; Statins; PCSK9 inhibitors},
   language = {eng},
   issn = {1523-3804},
   journal = {CURRENT ATHEROSCLEROSIS REPORTS},
   title = {Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?},
   url = {https://link.springer.com/article/10.1007/s11883-023-01166-3},
   volume = {25},
   year = {2023}
}

TY  - JOUR
ID  - 2379567
AU  - Poloczková, Hana - Krejčí, Jan
PY  - 2023
TI  - Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
JF  - CURRENT ATHEROSCLEROSIS REPORTS
VL  - 25
IS  - 12
SP  - 957-964
EP  - 957-964
PB  - CURRENT MEDICINE GROUP
SN  - 15233804
KW  - Heart failure
KW  - Dyslipidemia
KW  - Lipid lowering therapy
KW  - Statins
KW  - PCSK9 inhibitors
UR  - https://link.springer.com/article/10.1007/s11883-023-01166-3
N2  - Purpose of ReviewAn evidence for lipid lowering therapy in heart failure is briefly summarized in this review.Recent FindingsHeart failure therapy is based on recent guidelines for diagnosis and treatment of acute and chronic heart failure. The question of the importance of hypolipidemic treatment in heart failure remains insufficiently answered. We still rely only on results of two randomized controlled trials that did not show significant benefit of statins on mortality in these patients. In contrast, some meta-analysis, prospective or retrospective cohorts, found some positive effects of this therapy. Recently, the role of inflammation and the possibility of its influence by hypolipidemics have been discussed. PCSK9 inhibitors, new lipid lowering drugs, are very effective in LDL-cholesterol lowering and atherosclerotic cardiovascular diseases prevention. The role of PCSK9 inhibitors in heart failure treatment is investigated.SummaryBased on current knowledge, hypolipidemics are not generally recommended in heart failure therapy, unless there is another indication for their use.
ER  -

POLOCZKOVÁ, Hana a Jan KREJČÍ. Heart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy? \textit{CURRENT ATHEROSCLEROSIS REPORTS}. PHILADELPHIA: CURRENT MEDICINE GROUP, 2023, roč.~25, č.~12, s.~957-964. ISSN~1523-3804. Dostupné z: https://dx.doi.org/10.1007/s11883-023-01166-3.

Podrobný výpis o publikaci